Status:

COMPLETED

Effectiveness and Safety of Pharmacopuncture Therapy for Patients with Lumbar Spinal Stenosis

Lead Sponsor:

Jaseng Medical Foundation

Conditions:

Lumbar Spinal Stenosis

Eligibility:

All Genders

19-69 years

Phase:

NA

Brief Summary

This is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the con...

Detailed Description

This is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the con...

Eligibility Criteria

Inclusion

  • Diagnosed with lumbar spinal stenosis based on radiology including computed tomography or magnetic resonance imaging.
  • Clear neurogenic claudication symptoms existed (symptoms aggravated with walking, and alleviated upon resting in lumbar flexion position).
  • reported radiating leg pain or low back pain (LBP) with intensity of NRS ≥5
  • Between the age of 19 and 69 years old.
  • Participants who agreed to participate the study and voluntarily signed the informed consent form.

Exclusion

  • Patients with vascular claudication
  • Patients with pathologies of non-spinal origin that may cause LBP or radiating leg pain (e.g. spinal tumor, fracture)
  • Patients with soft tissue pathologies that may cause LBP or radiating leg pain (e.g. tumor, fibromyalgia, rheumatoid arthritis, gout)
  • Patients with other systemic diseases that may interfere with treatment effect or outcome interpretation
  • Patients who administrate those prescribed medicine that may interfere with interpretation of the result (e.g. corticosteroids, immunosuppressants, physchotropic drugs)
  • Patients for whom pharmacopuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, serious diabetes with risk of infection)
  • Patients who were treated with one of the following intervention within the past week; medicine that may potentially influence pain such as NSAIDs (nonsteroidal antiinflammatory drugs), pharmacopuncture, or physical therapies.
  • Pregnant patients or patients planning pregnancy
  • Patients with medical history of spinal surgery within the past 3 months
  • Previous participation in other clinical studies within 1 month of current study enrollment, or plans to participate in other clinical studies during participation (including follow-up period) of the current study after study enrollment
  • Patients unable to fill out study participation consent form
  • Patients deemed unsuitable for study participation as assessed by the researchers

Key Trial Info

Start Date :

April 13 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 28 2024

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT05242497

Start Date

April 13 2022

End Date

October 28 2024

Last Update

January 9 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Dongguk University Bundang Oriental Hospital

Seongnam-si, Bundang-gu, South Korea, 13601

2

Kyung Hee University Korean Medicine Hospital

Seoul, Dongdaemun-gu, South Korea, 130-701

3

Kyung Hee University Korean Medicine Hospital at Gangdong

Seoul, Gangdong-gu, South Korea, 05278

4

Jaseng Hospital of Korean Medicine

Seoul, Gangnam-Gu, South Korea, 135-896

Effectiveness and Safety of Pharmacopuncture Therapy for Patients with Lumbar Spinal Stenosis | DecenTrialz